December 12, 2000
Taisho Expands Diabetes Collaboration with Neurocrine
Taisho Pharmaceutical Co., Ltd. (President, Akira Uehara) announced today that it has expanded its collaboration with Neurocrine Biosciences Inc. (President, Gary A. Lyons) providing exclusive rights to develop and commercialize Neurocrine's altered peptide ligand (APL) for diabetes, in North America and other countries outside of Europe and Asia. In July 2000 Neurocrine licensed to Taisho the exclusive rights to develop and commercialize NBI-6024 in Europe and Asia. With the expanded agreement Taisho and Neurocrine will collaborate in the worldwide clinical development of NBI-6024.
NBI-6024 is the peptide whose insulin construction is altered using Neurocrine Biosciences' proprietary altered peptide ligand (APL) technology; developments for its application in treating type 1 diabetes are advancing. In patients with type 1 diabetes, a breakdown in the beta cells of produced insulin occurs, and this is accentuated by the immune system. NBI-6024 retards the deterioration of beta cells by altering the Th-1-to-Th-2 balance of the T cells. In this manner, NBI-6024 is thought to have applications in controlling the advancement of diabetes, and there is also promise for application as a treatment of the group of type 2 diabetes patients previously diagnosed as type 1.5.
Diabetes is a life-long condition, and, prior to the development of NBI-6024, immuno-tolerance treatments did not exist. Initiating treatments with NBI-6024 during the early stages of type 1 diabetes will significantly slow the advancement of the condition. We are confident that this will enhance quality of life in people with diabetes and, as a type 1 diabetes treatment, will benefit all sufferers of insulin-dependent diabetes mellitus (IDDM), from children to adults.
Neurocrine Biosciences,Inc. is a neuro-science oriented bio-pharmaceutical firm, and currently, they have five new medical products at the clinical development stage.
Taisho is currently engaged in bolstering research capabilities in its prescription drug operation, and is actively seeking cooperative engagements with biotechnology firms. This agreement is completely beneficial to both Taisho focusing diabetes area, and Neurocrine seeking a business partners.